Clinical trials
Patients With Advanced Solid Tumors clinical trials
Below are recruiting patients with advanced solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,060 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT07310134RecruitingPhase 1
Study of ZX-8177 for advanced solid tumors
This trial tests a new oral drug (ZX-8177) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with standard options. The goal is to see if it is safe and helps control the disease.
ShanghaiAges 18 years+ - NCT06212076RecruitingPhase 1/Phase 2
Testing IPG1094 for advanced solid tumors
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06820424RecruitingEarly Phase 1
CDH17-targeted CAR-T cells for advanced solid tumors
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
Kunming, YunnanAges 18–75 - NCT06239298RecruitingPhase 1/Phase 2
Testing ZG005 plus donafenib for advanced solid tumors
This trial tests two drugs, ZG005 and donafenib, together in people with advanced solid tumors that have not responded to other treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07417189RecruitingPhase 1/Phase 2
Study of ABSK141 for advanced solid tumors with KRAS G12D mutation
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
ShanghaiAges 18 years+ - NCT06084286RecruitingPhase 1
CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Chengdu, SichuanAges 18–75 - NCT06249256RecruitingEarly Phase 1
Fast CAR T cells for advanced solid tumors
This trial tests a new type of CAR-T cell therapy called Fast CAR T cells for people with advanced solid tumors. It is designed for patients whose tumors have certain markers (mesothelin and PD-L1) and who have not responded to or cannot tolerate standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06081907RecruitingPhase 1/Phase 2
IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Changsha, HunanAges 18–75 - NCT07639450RecruitingPhase 1/Phase 2
N-3C01 Cancer Treatment Study for Advanced Solid Tumors
This trial tests a new drug called N-3C01, alone or combined with immune-boosting medications, in patients whose advanced cancer has stopped responding to standard treatments. The goal is to see if this approach can slow or shrink tumors that have become resistant to other therapies.
Saint Leonards, New South WalesAges 18–75 - NCT06710158RecruitingPhase 1
SC-102 for advanced solid tumors
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06773091RecruitingPhase 1
NK cell therapy for advanced solid tumors
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
BeijingAges 18–70 - NCT07045454RecruitingPhase 1
MHB118C shot for advanced solid tumors
This trial tests an injection called MHB118C for people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The goal is to see if this new drug can help shrink tumors or slow their growth.
ShanghaiAges 18 years+ - NCT06717022Recruiting
CHT102 for mesothelin-positive advanced solid tumors
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06770569RecruitingPhase 1
Study of HRS-3802 for advanced solid tumors
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
Saint Leonards, New South WalesAges 18 years+ - NCT07380334RecruitingPhase 1
Studying SHR-1049 for advanced solid tumors
This study is testing a new drug called SHR-1049 for people with advanced solid tumors (cancers that have spread). It looks at safety, how the drug moves through the body, and whether it helps shrink tumors. You may be eligible if you have tried standard treatment without success or no standard treatment exists.
Hangzhou, ZhejiangAges 18–75 - NCT07380386RecruitingPhase 1/Phase 2
SKB105 injection for advanced solid tumors
This trial tests a new drug called SKB105 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07230977RecruitingPhase 1
GenSci139 for advanced solid tumors
This Phase 1 trial tests an experimental drug called GenSci139 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Jinan, ShandongAges 18 years+ - NCT07083323RecruitingPhase 1/Phase 2
Study of HY05350 for mesothelin-positive advanced solid tumors
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT05836948RecruitingPhase 1
Testing SHR-9839 for advanced solid tumors
This Phase 1 trial studies SHR-9839, a new injection medicine, for people with advanced solid tumors that can’t be removed by surgery and have returned or stopped responding to standard care. It mainly aims to find a safe dose and see early signs of whether the treatment can work.
Hangzhou, ZhejiangAges 18–70 - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07368478RecruitingPhase 1
Study of BC2027 for advanced solid tumors with GPC3
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Shanghai, Shanghai, ChinaAges 18 years+ - NCT06651593RecruitingPhase 2
BND-22 and cemiplimab for advanced solid tumors
This trial tests a combination of two new drugs, BND-22 and cemiplimab, for people with certain advanced solid tumors like lung, colorectal, or ovarian cancer. It aims to see if this treatment helps control the cancer and looks at specific markers in your blood and tissue.
Houston, TexasAges 18 years+
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patients with advanced solid tumors?
- Yes. Clin2 currently lists 1,060 recruiting patients with advanced solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patients with advanced solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patients with advanced solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Advanced Solid Tumor
- Advanced Malignant Solid Neoplasm
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.